Targeting PI3K signalling in cancer: opportunities, challenges and limitations

被引：2015

作者：

Engelman, Jeffrey A. ^{[1
]}

机构：

[1] Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02129 USA

来源：

NATURE REVIEWS CANCER | 2009年 / 9卷 / 08期

基金：

美国国家卫生研究院;

关键词：

GROWTH-FACTOR RECEPTOR; CELL LUNG-CANCER; TYROSINE KINASE INHIBITORS; TUMOR-SUPPRESSOR GENE; PHOSPHATIDYLINOSITOL 3-KINASE/MAMMALIAN TARGET; PHOSPHOINOSITIDE 3-KINASE/AKT PATHWAY; RICTOR-MTOR COMPLEX; ANTITUMOR-ACTIVITY; BREAST-CANCER; ACQUIRED-RESISTANCE;

D O I：

10.1038/nrc2664

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

There are ample genetic and laboratory studies that suggest the PI3K-Akt pathway is vital to the growth and survival of cancer cells. Inhibitors targeting this pathway are entering the clinic at a rapid pace. In this Review, the therapeutic potential of drugs targeting PI3K-Akt signalling for the treatment of cancer is discussed. I focus on the advantages and drawbacks of different treatment strategies for targeting this pathway, the cancers that might respond best to these therapies and the challenges and limitations that confront their clinical development.

引用

页码：550 / 562

页数：13

共 160 条

[81] PTEN: a tumour suppressor that functions as a phospholipid phosphatase [J].

Maehama, T ;

Dixon, JE .

TRENDS IN CELL BIOLOGY, 1999, 9 (04) :125-128

[82] Detection of mutations in EGFR in circulating lung-cancer cells [J].

Maheswaran, Shyamala ;

Sequist, Lecia V. ;

Nagrath, Sunitha ;

Ulkus, Lindsey ;

Brannigan, Brian ;

Collura, Chey V. ;

Inserra, Elizabeth ;

Diederichs, Sven ;

Iafrate, A. John ;

Bell, Daphne W. ;

Digumarthy, Subba ;

Muzikansky, Alona ;

Irimia, Daniel ;

Settleman, Jeffrey ;

Tompkins, Ronald G. ;

Lynch, Thomas J. ;

Toner, Mehmet ;

Haber, Daniel A. .

NEW ENGLAND JOURNAL OF MEDICINE, 2008, 359 (04) :366-377

[83] Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity [J].

Maira, Sauveur-Michel ;

Stauffer, Frederic ;

Brueggen, Josef ;

Furet, Pascal ;

Schnell, Christian ;

Fritsch, Christine ;

Brachmann, Saskia ;

Chene, Patrick ;

De Pover, Alain ;

Schoemaker, Kevin ;

Fabbro, Doriano ;

Gabriel, Daniela ;

Simonen, Marjo ;

Murphy, Leon ;

Finan, Peter ;

Sellers, William ;

Garcia-Echeverria, Carlos .

MOLECULAR CANCER THERAPEUTICS, 2008, 7 (07) :1851-1863

[84] mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways [J].

Majumder, PK ;

Febbo, PG ;

Bikoff, R ;

Berger, R ;

Xue, Q ;

McMahon, LM ;

Manola, J ;

Brugarolas, J ;

McDonnell, TJ ;

Golub, TR ;

Loda, M ;

Lane, HA ;

Sellers, WR .

NATURE MEDICINE, 2004, 10 (06) :594-601

[85] Activating E17K mutation in the gene encoding the protein kinase AKT1 in a subset of squamous cell carcinoma of the lung [J].

Malanga, Donatella ;

Scrima, Marianna ;

De Marco, Carmela ;

Fabiani, Fernanda ;

De Rosa, Nicla ;

De Gisi, Silvia ;

Malara, Natalia ;

Savino, Rocco ;

Rocco, Gaetano ;

Chiappetta, Gennaro ;

Franco, Renato ;

Tirino, Virginia ;

Pirozzi, Giuseppe ;

Viglietto, Giuseppe .

CELL CYCLE, 2008, 7 (05) :665-669

[86] Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-Kinase/Akt pathway [J].

Manning, BD ;

Tee, AR ;

Logsdon, MN ;

Blenis, J ;

Cantley, LC .

MOLECULAR CELL, 2002, 10 (01) :151-162

[87] United at last: the tuberous sclerosis complex gene products connect the phosphoinositide 3-kinase/Akt pathway to mammalian target of rapamycin (mTOR) signalling [J].

Manning, BD ;

Cantley, LC .

BIOCHEMICAL SOCIETY TRANSACTIONS, 2003, 31 :573-578

[88] Akt1 ablation inhibits, whereas Akt2 ablation accelerates, the development of mammary adenocarcinomas in mouse mammary tumor virus (MMTV)-ErbB2/Neu and MMTV-polyoma middle T transgenic mice [J].

Maroulakou, Ioanna G. ;

Oemler, William ;

Naber, Stephen P. ;

Tsichlis, Philip N. .

CANCER RESEARCH, 2007, 67 (01) :167-177

[89]

Massion PP, 2002, CANCER RES, V62, P3636

[90] Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors [J].

Mellinghoff, IK ;

Wang, MY ;

Vivanco, I ;

Haas-Kogan, DA ;

Zhu, SJ ;

Dia, EQ ;

Lu, KV ;

Yoshimoto, K ;

Huang, JHY ;

Chute, DJ ;

Riggs, BL ;

Horvath, S ;

Liau, LM ;

Cavenee, WK ;

Rao, PN ;

Beroukhim, R ;

Peck, TC ;

Lee, JC ;

Sellers, WR ;

Stokoe, D ;

Prados, M ;

Cloughesy, TF ;

Sawyers, CL ;

Mischel, PS .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (19) :2012-2024

← 4 5 6 7 8 9 10 11 12 13 →